Any current/future new fundraising through debt or equity?

Rainbow Children's Medicare Limited currently has a robust net cash position of INR 515.9 crores as of March 31, 2024. The company is confident of funding its ongoing and planned capital expenditure entirely through internal accruals. There is no need for debt financing to support capital expenditures as per current cash flows and expected accruals. No mention of any planned or ongoing fundraising through equity or debt was made during the call. Management emphasized completing all planned capex through internal resources without incurring new debt.

Any current/future capex/capital investment/strategic investment?

The company is progressing on multiple new hospital projects: - Spoke Hospital at Hennur, Bangalore (60 beds) and Rajahmundry, Andhra Pradesh (100 beds) expected to commence operations in Q4 FY25. - Regional spoke hospital in Coimbatore project has begun, expected to complete in about 24 months. - Land parcels in Gurgaon have been received possession letters; architectural designs are being finalized with groundbreaking expected in 3-4 months. IVF services expansion: - Increased from 3 to 11 centers providing IVF within existing hospitals. - Capex for IVF centers estimated at INR 1.

Future growth expectations in sales/revenue/volumes?

Rainbow Children's Medicare expects mid-teen revenue growth (around 15-18%) in the coming years, maintaining disciplined growth aligned with top-line and bottom-line expansion. Volume growth, particularly inpatient (IP) and outpatient (OP) volumes, is anticipated to improve following a muted previous year affected by seasonality and external factors like delayed monsoons and cyclones. The company targets about 55% occupancy in FY25, signaling a return to normal seasonal patterns, which should boost volumes and revenues. Deliveries grew by 7% last year, and fertility (IVF) services expans

Future growth expectations in earnings/operating earnings/profits/EPS?

Rainbow Children's Medicare expects mid-teens revenue growth (~15-18%) in coming years, leading to proportional bottom-line growth. EBITDA margins may moderate temporarily due to ongoing capacity additions. ARPOB (Average Revenue Per Occupied Bed) growth is expected to be flat or slightly up/down (~±1%) in FY25; focus is on volume and occupancy growth. Occupancy is targeted around 55% in FY25, supporting better revenue and EBITDA. International business is expected to grow from 3.4% to about 5% of revenue in FY25, aiding top-line expansion. New hospitals are currently incurring losse

Rainbow Child.Q4 FY24Healthcare Services

Rainbow Child. Q4 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹1,280P/E: 48.7Market Cap: ₹14.0K CrSector: Healthcare Services

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3

Rainbow Children's Medicare expects mid-teen revenue growth (around 15-18%) in the coming years, maintaining disciplined growth aligned with top-line and bottom-line expansion.
Volume growth, particularly inpatient (IP) and outpatient (OP) volumes, is anticipated to improve following a muted previous year affected by seasonality and external factors like delayed monsoons and cyclones.
The company targets about 55% occupancy in FY25, signaling a return to normal seasonal patterns, which should boost volumes and revenues.
Deliveries grew by 7% last year, and fertility (IVF) services expansion is expected to contribute to growth, with IVF now offered in 11 centers versus three previously.
Insurance penetration is increasing, improving revenue quality, though ARPOB (average revenue per occupied bed) growth is expected to be flat or modest (+/- 1%) in FY25.
International business, currently ~3.4% of revenue, is targeted to grow to about 5% in FY25.

Margin guidance

Category 3

Rainbow Children's Medicare expects mid-teens revenue growth (~15-18%) in coming years, leading to proportional bottom-line growth.
EBITDA margins may moderate temporarily due to ongoing capacity additions.
ARPOB (Average Revenue Per Occupied Bed) growth is expected to be flat or slightly up/down (~±1%) in FY25; focus is on volume and occupancy growth.
Occupancy is targeted around 55% in FY25, supporting better revenue and EBITDA.
International business is expected to grow from 3.4% to about 5% of revenue in FY25, aiding top-line expansion.
New hospitals are currently incurring losses but anticipated to breakeven after initial ramp-up (update expected in coming quarters).
Overall disciplined approach to growth, balancing investments with profitability, with PAT growth expected to follow revenue growth trajectory.

See what Rainbow Child. management said on margin guidance — free account, 30 seconds.

Fundraise plans

Rainbow Children's Medicare Limited currently has a robust net cash position of INR 515.9 crores as of March 31, 2024.
The company is confident of funding its ongoing and planned capital expenditure entirely through internal accruals.
There is no need for debt financing to support capital expenditures as per current cash flows and expected accruals.
No mention of any planned or ongoing fundraising through equity or debt was made during the call.
Management emphasized completing all planned capex through internal resources without incurring new debt.

Order book

The transcript for Rainbow Children's Medicare Limited's Q4 & FY24 earnings call does not explicitly mention details about the current or expected order book or pending orders. However, relevant points related to ongoing projects and expansions include: - Commissioned 280 beds in the last quarter across three new spoke hospitals in Hyderabad, Bangalore, and Chennai. - Additional new block added at the existing hospital in Hydernagar, Hyderabad. - Operations now include over 2,000 beds, including managed beds in Delhi. - Upcoming projects: - Spoke Hospital at Hennur, Bangalore (60 beds) and regional spoke hospital in Rajahmundry, Andhra Pradesh (100 beds) expected to commence operations in Q4 FY25. - Regional spoke hospital in Coimbatore project has just begun; expected completion in 24 months. - Land parcels in Gurgaon received possession letters; ground-breaking expected in 3-4 months. No financial order book or pending orders data were mentioned.

See what Rainbow Child. management said on order book — free account, 30 seconds.

Capex plans

Yes

The company is progressing on multiple new hospital projects:
- Spoke Hospital at Hennur, Bangalore (60 beds) and Rajahmundry, Andhra Pradesh (100 beds) expected to commence operations in Q4 FY25.
- Regional spoke hospital in Coimbatore project has begun, expected to complete in about 24 months.
- Land parcels in Gurgaon have been received possession letters; architectural designs are being finalized with groundbreaking expected in 3-4 months.
IVF services expansion:
- Increased from 3 to 11 centers providing IVF within existing hospitals.
- Capex for IVF centers estimated at INR 1.5-1.75 crore each, integrated within hospital development.
- Plans to add more IVF services in existing and upcoming hospitals.
For Q4 FY24, about INR 50 crores was invested in capital expenditure.
The company is confident of funding all ongoing and planned capex through internal accruals without debt financing.

Track Rainbow Child. — get its next earnings analysis in your feed

How does Rainbow Child. rank vs peers in Healthcare Services?

Pro feature

ThisRainbow Child.

Rev 3Mar 3

See where Rainbow Child. sits in Healthcare ServicesSee which companies these are, and every other name in the sector.Open rankings

How does Rainbow Child. rank in Healthcare Services?

Compare Rainbow Child. against every Healthcare Services company (Q4 FY24) on revenue, margins and earnings-call signals.

View Healthcare Services leaderboard →

What Rainbow Child.'s management said in earlier quarters

Others in Healthcare Services this season

KMC Speciality Hospitals (India) Ltd (Q4 FY26)
Q4 FY’26 Revenue from Operations: INR 82.3 Cr, up 35.0% YoY from INR 60.9 Cr in Q4 FY’25 (Page 20) . Key concall takeaways from KMC Speciality Hospitals…
KMC Speciality Hospitals (India) Ltd (Q1 FY27)
Q1 FY'27 Revenue from operations: INR 91.8 Cr, up 38% YoY from INR 66.6 Cr in Q1 FY'26. Key concall takeaways from KMC Speciality Hospitals (India) Ltd's Q1…
Suven Life Sciences Ltd (Q1 FY22)
The provided pages of the Suven Life Sciences investor presentation do not contain any specific revenue, sales, or volume figures for any quarter. Key concall…
Vimta Labs Ltd (Q3 FY25)
Q3 FY25 Revenue from Operations: ₹899 Mn . Key concall takeaways from Vimta Labs Ltd's Q3 FY25 earnings call — and how it ranks against sector peers.

Compare:vs Apollo Hospitals Enterprise Ltd vs Max Healthcare vs Manipal Health

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Rainbow Child. Q4 FY24 Earnings Call Analysis

Revenue guidance

Fundraise plans

Capex plans

How does Rainbow Child. rank in Healthcare Services?

Continue your research

What Rainbow Child.'s management said in earlier quarters

Others in Healthcare Services this season